Business Development
Amulet adopts a flexible approach to its business model with the specific intention of enabling it to consider partnership and out-licensing arrangements for both its primary Gastrointestinal-focused programs as well as secondary indications. The company is committed to seeing NORTECH™ technology adopted into the widest possible range of therapeutic applications.
Business Proposition
Our NORTECH™ technology offers potential partners an exciting opportunity underpinned by:
- Strong, unencumbered IP protection
- Established safety profile with significant advantages over existing technologies
- Deep and broad pipeline with a strong GI focus
- Short development horizon from pre-clinical to NDA
Areas for Partner Consideration
- Gastroparesis
- Obesity
- Enteral feeding in critical care patients
- Irritable bowel syndrome
- Functional dyspepsia
- Wounds
- Diabetes therapeutics
- Pain therapeutics
- Glaucoma
Interested parties should contact:
Craig Liddell PhDChairman & CEO
Amulet Pharmaceuticals, Inc
Email: cliddell@amuletpharma.com
Main Phone: 240-499-2740